2024 World Conference on Lung Cancer (WCLC) - Posters-P3.03I.16 Treatment Outcomes in Patients who Received Bevacizumab Therapy for Radiation Induced Brain Necrosis

Pdf Summary

The study evaluates the treatment outcomes of patients who received bevacizumab therapy for radiation-induced brain necrosis (RBN). The primary objective is to determine whether patients benefited clinically from this treatment. Secondary objectives include assessing if the clinical benefits varied based on bevacizumab dosing strategy, examining the safety of the treatment, and comparing outcomes using bevacizumab and its biosimilar, bevacizumab-awwb.<br /><br />The study involved a retrospective chart review of 26 patients treated with bevacizumab for RBN between January 1, 2015, and January 31, 2024. The median age of the cohort was 66 years, with a slightly higher percentage of female patients (57.7%). Most patients in the study had non-small cell lung cancer as their primary pathology.<br /><br />Results showed that on average, patients experienced clinical benefits after four cycles of bevacizumab with a manageable safety profile, indicating the treatment is well-tolerated among older populations. The clinical benefits appeared consistent regardless of the dosing strategy, frequency, or whether bevacizumab or its biosimilar was used. Specifically, a significant number of patients (91.9%) showed clinical improvement.<br /><br />Treatment-related adverse events included hypertension, fatigue, bleeding, and serum creatinine elevations, among others. Nevertheless, the study demonstrated significant clinical improvements and tolerable side effect profiles, reinforcing bevacizumab's efficacy and safety for managing RBN.<br /><br />Disclosure statements reveal potential financial or personal relationships with companies producing bevacizumab or related therapies by some investigators, indicating potential conflicts of interest. Nonetheless, the study provides novel insights, such as being the first to compare bevacizumab and its biosimilar in this patient population.

Asset Subtitle

Jenoy Merchant

Meta Tag

Speaker Jenoy Merchant

Topic Tumor Biology – Translational Biology

Keywords

bevacizumab therapy

radiation-induced brain necrosis

clinical benefits

dosing strategy

safety profile

biosimilar bevacizumab-awwb

retrospective chart review

treatment-related adverse events

non-small cell lung cancer

conflicts of interest